Tumor angiogenesis, essential for tumor growth and metastasis, is tightly regulated by VEGF/VEGFR and PDGF/PDGFR pathways, and therefore blocking those pathways is a promising therapeutic target. Compared to sunitinib, the C(5)-Br derivative of 2-pyrrolidone-fused (2-oxoindolin-3-ylidene)methylpyrrole has significantly greater in vitro activities against VEGFR-2, PDGFRβ, and tube formation. | Structural optimization and evaluation of novel 2-pyrrolidone-fused 2-oxoindolin-3-ylidene methylpyrrole derivatives as potential VEGFR-2 PDGFRβ inhibitors
